Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program on July 28, 2026 anti-TSHR centanafadine Drug Enforcement Administration NDSRI Otsuka reverse merger SIMTRIYO Thyroid associated opthalmopathies United States Food and Drug Administration Vyne yarrow flower extract YARW YB-101 +
Lumvoa emerges as strong Tepezza rival—but SC Tepezza looms on the horizon on July 09, 2026 Amgen Approved IGF1R protein, human Lumvoa subcutaneous Tepezza Thyroid associated opthalmopathies United States Food and Drug Administration Viridian +
Ethyreal Bio emerges with $101M to challenge Amgen’s Tepezza in thyroid eye disease on June 10, 2026 Amgen Amgen 's anti-TSHR antibody Avoro Capital Cervical Atlas Ethyreal Bio Graves Disease Tepezza Thyroid associated opthalmopathies venture +
Immunovant's Batoclimab FcRn Inhibitor Fails Phase 3 Trials in Thyroid Eye Disease on April 02, 2026 Batoclimab FCGRT gene Immunovant NALF2 gene Thyroid associated opthalmopathies +
RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci on December 17, 2025 anti-TSHR antibody Antibodies Autoimmune Changchun GeneScience Pharmaceutical China GenSci GS-098 Investments RTW strategic partnership Thyroid associated opthalmopathies Yarrow Bioscience YB-101 +
Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market on July 31, 2025 Antibodies Biopharma Clinical Trials Dosage Forms Japan Kissei Partnership Thyroid associated opthalmopathies veligrotug Viridian VRDN-003 +